Myelofibrosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelofibrosis}}
{{Myelofibrosis}}
{{CMG}}{{AE}}{{SR}}
{{CMG}}{{Sab}}{{AE}}{{SR}}


==Overview==
==Overview==
Line 7: Line 7:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
*In the countries of the European Union, the [[incidence]] of [[myelofibrosis]] ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average [[incidence]] of 1.1 per 100,000 persons.<ref name="pmid24372927" />
*In Olmstead County, Minnesota USA, the annual [[incidence]] of [[Primary myelofibrosis|primary myelofibrosis (PMF)]] has been reported to be 1.33 per 100,000.<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>
===Prevalence===
===Prevalence===
*The [[prevalence]] of [[myelofibrosis]] is approximately 1 per 100,000 individuals worldwide.<ref name="epidemiologyofmyelofibrosis1radio1">Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016</ref>
*The [[prevalence]] of [[myelofibrosis]] is approximately 1 per 100,000 individuals worldwide.
*In developed countries, the [[prevalence]] of [[myelofibrosis]] is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref>
*In developed countries, the [[prevalence]] of [[myelofibrosis]] is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref>
===Incidence===
===Case-fatality rate/Mortality rate===
*In the countries of the European Union, the [[incidence]] of [[myelofibrosis]] ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average [[incidence]] of 1.1 per 100,000 persons.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref>
* In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*In Olmstead County, Minnesota USA, the annual [[incidence]] of [[Primary myelofibrosis|primary myelofibrosis (PMF)]] has been reported to be 1.33 per 100,000.<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>
* The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
[[Myelofibrosis]] is a [[disease]] that tends to affect the middle-aged and elderly population. The [[mean]] age at [[diagnosis]] is 60 years.<ref name="epidemiologyofmyelofibrosis1radio1">Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016</ref><ref name="pmid17312082">{{cite journal |vauthors=Cloran F, Banks KP |title=AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly |journal=AJR Am J Roentgenol |volume=188 |issue=3 Suppl |pages=S18–20 |date=March 2007 |pmid=17312082 |doi=10.2214/AJR.05.2141 |url=}}</ref><ref name="pmid9488952">{{cite journal |vauthors=Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E |title=[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients] |language=Spanish; Castilian |journal=Med Clin (Barc) |volume=109 |issue=17 |pages=651–5 |date=November 1997 |pmid=9488952 |doi= |url=}}</ref>
[[Myelofibrosis]] is a [[disease]] that tends to affect the middle-aged and elderly population. The [[mean]] age at [[diagnosis]] is 60 years.<ref name="pmid17312082">{{cite journal |vauthors=Cloran F, Banks KP |title=AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly |journal=AJR Am J Roentgenol |volume=188 |issue=3 Suppl |pages=S18–20 |date=March 2007 |pmid=17312082 |doi=10.2214/AJR.05.2141 |url=}}</ref><ref name="pmid9488952">{{cite journal |vauthors=Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E |title=[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients] |language=Spanish; Castilian |journal=Med Clin (Barc) |volume=109 |issue=17 |pages=651–5 |date=November 1997 |pmid=9488952 |doi= |url=}}</ref>
 
===Race===
*[[Myelofibrosis]] is more [[Prevalence|prevalent]] in the Ashkenazi Jews with an evidence of [[genetic]] [[Transmission (genetics)|transmission]].<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>


===Gender===
===Gender===
*Gender distribution can differ by the subtype of the [[disease]] with [[Primary myelofibrosis|primary myelofibrosis (PMF)]] being more [[Prevalence|prevalent]] in [[Male|males]] and post-[[essential thrombocythemia]] being more common in [[Female|females]].<ref name="pmid27540137">{{cite journal |vauthors=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA |title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group |journal=Haematologica |volume=102 |issue=1 |pages=85–93 |date=January 2017 |pmid=27540137 |pmc=5210236 |doi=10.3324/haematol.2016.149559 |url=}}</ref>
*Gender distribution can differ by the subtype of the [[disease]] with [[Primary myelofibrosis|primary myelofibrosis (PMF)]] being more [[Prevalence|prevalent]] in [[Male|males]] and post-[[essential thrombocythemia]] being more common in [[Female|females]].<ref name="pmid27540137">{{cite journal |vauthors=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA |title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group |journal=Haematologica |volume=102 |issue=1 |pages=85–93 |date=January 2017 |pmid=27540137 |pmc=5210236 |doi=10.3324/haematol.2016.149559 |url=}}</ref>
*[[Male|Males]] are more commonly affected with [[myelofibrosis]] than [[Female|females]] with a [[male]] to [[female]] ratio of approximately 1.5 to 1.<ref name="pmid22212965">{{cite journal| author=Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al.| title=One thousand patients with primary myelofibrosis: the mayo clinic experience. | journal=Mayo Clin Proc | year= 2012 | volume= 87 | issue= 1 | pages= 25-33 | pmid=22212965 | doi=10.1016/j.mayocp.2011.11.001 | pmc=PMC3538387 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22212965  }} </ref>
*[[Male|Males]] are more commonly affected with [[myelofibrosis]] than [[Female|females]] with a [[male]] to [[female]] ratio of approximately 1.5 to 1.<ref name="pmid22212965">{{cite journal| author=Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al.| title=One thousand patients with primary myelofibrosis: the mayo clinic experience. | journal=Mayo Clin Proc | year= 2012 | volume= 87 | issue= 1 | pages= 25-33 | pmid=22212965 | doi=10.1016/j.mayocp.2011.11.001 | pmc=PMC3538387 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22212965  }} </ref>
===Race===
*[[Myelofibrosis]] is more [[Prevalence|prevalent]] in the Ashkenazi Jews with an evidence of [[genetic]] [[Transmission (genetics)|transmission]].<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>


==References==
==References==

Latest revision as of 15:20, 12 November 2019

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis epidemiology and demographics

CDC on Myelofibrosis epidemiology and demographics

Myelofibrosis epidemiology and demographics in the news

Blogs on Myelofibrosis epidemiology and demographics

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Sabawoon Mirwais, M.B.B.S, M.D.[2]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [3]

Overview

The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population with a mean age of 60 years at diagnosis. Males are more commonly affected than females. The male to female ratio is approximately 1.5 to 1. Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.

Epidemiology and Demographics

Incidence

Prevalence

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[3][4]

Race

Gender

References

  1. 1.0 1.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
  2. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  3. Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.
  4. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (November 1997). "[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]". Med Clin (Barc) (in Spanish; Castilian). 109 (17): 651–5. PMID 9488952.
  5. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  6. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (January 2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.
  7. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.


Template:WikiDoc Sources